Evercore ISI Forecasts Strong Price Appreciation for Abbott Laboratories (NYSE:ABT) Stock

Abbott Laboratories (NYSE:ABT) had its price objective upped by analysts at Evercore ISI from $142.00 to $144.00 in a research report issued to clients and investors on Monday,MarketScreener reports. The brokerage presently has an “outperform” rating on the healthcare product maker’s stock. Evercore ISI’s target price would indicate a potential upside of 12.58% from the company’s current price.

A number of other equities research analysts also recently commented on ABT. Benchmark assumed coverage on Abbott Laboratories in a research report on Friday, October 10th. They issued a “buy” rating and a $145.00 target price on the stock. Sanford C. Bernstein boosted their price objective on shares of Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Abbott Laboratories in a research report on Monday, December 29th. Raymond James Financial lifted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Finally, Daiwa Capital Markets upped their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $147.47.

Abbott Laboratories Stock Performance

NYSE ABT opened at $127.91 on Monday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock’s fifty day moving average is $126.00 and its two-hundred day moving average is $129.51. The firm has a market capitalization of $222.42 billion, a P/E ratio of 16.03, a price-to-earnings-growth ratio of 2.09 and a beta of 0.72. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. The company had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. Abbott Laboratories’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Institutional Trading of Abbott Laboratories

Several hedge funds have recently added to or reduced their stakes in the company. Werlinich Asset Management LLC raised its holdings in shares of Abbott Laboratories by 8.9% in the 4th quarter. Werlinich Asset Management LLC now owns 15,645 shares of the healthcare product maker’s stock valued at $1,968,000 after purchasing an additional 1,275 shares in the last quarter. Farmers Trust Co. raised its stake in Abbott Laboratories by 0.8% in the fourth quarter. Farmers Trust Co. now owns 19,024 shares of the healthcare product maker’s stock valued at $2,384,000 after buying an additional 145 shares in the last quarter. Avior Wealth Management LLC lifted its holdings in Abbott Laboratories by 0.3% during the 4th quarter. Avior Wealth Management LLC now owns 42,763 shares of the healthcare product maker’s stock worth $5,358,000 after buying an additional 112 shares during the last quarter. Doliver Advisors LP lifted its holdings in Abbott Laboratories by 8.5% during the 4th quarter. Doliver Advisors LP now owns 16,736 shares of the healthcare product maker’s stock worth $2,097,000 after buying an additional 1,309 shares during the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays reaffirmed a constructive view on ABT with a buy/overweight stance and raised its price target, signaling strong analyst confidence that supports further upside. Barclays Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Barclays also increased its price target from $162 to $169 (overweight), implying meaningful upside from current levels and likely supporting buying interest. Benzinga coverage of Barclays PT raise
• Positive Sentiment: Evercore ISI nudged its target up to $144 and maintained an outperform rating, adding another independent analyst vote of confidence for valuation and growth expectations. Evercore ISI adjusts PT on Abbott Laboratories
• Positive Sentiment: Abbott unveiled Libre Assist, an AI-driven feature in the Libre app aimed at in-the-moment meal guidance for people with diabetes — a product extension that could boost user engagement and CGM stickiness. Product innovation at CES supports the narrative of recurring revenue and device ecosystem strength. Abbott’s new Libre Assist app feature
• Neutral Sentiment: Abbott scheduled its Q4 2025 earnings release and conference call for Jan. 22 (pre-market). This is a key near-term catalyst: results and FY guidance will likely drive the next leg of the stock’s move. Abbott hosts conference call for fourth-quarter earnings
• Neutral Sentiment: Studio coverage and comparisons (Zacks) highlight valuation comparisons with peers like Prestige Consumer Healthcare — useful for value-oriented investors, but not a direct stock driver. PBH vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Recent intraday/short-term coverage noting ABT’s outperformance versus the market signals momentum but is not a fundamental change. Abbott (ABT) Rises Higher Than Market: Key Facts

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.